|
NXTC | Nextcure, Inc. |
| Pharmaceutical Preparations |
| Book value per $ invested | $ 0.69 |
| Leverage | 30.17% |
| Market Cap | $ 140.4m |
| PE | 0.00 |
| Dividend Yield | 0.00% |
| Profit | $ -54.6m |
| Margin | -3811.46% |
NextCure, Inc., a clinical-stage biopharmaceutical company, is dedicated to the discovery and development of novel immunomedicines to treat cancer and other diseases related to the immune system by restoring normal immune function. The company is headquartered in Beltsville, Maryland.